Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of delgocitinib cream in adult lichen sclerosus
2025-524873-17-00Phase 3Authorised
- Sponsor
- LEO Pharma
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in Kraurosis vulvae comparing Delgocitinib cream with Cream vehicle (2 arms). Primary endpoint: Achieving IGA-LS TS at Week 12. Planned start Jul 2026; status: authorised.
02
Drugs
delgocitinib
03
Conditions
Kraurosis vulvae
Beyond the preview
Go deeper on 2025-524873-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524873-17-00.